Paige.AI, a New York City-based computational pathology startup focused on cancer diagnosis and treatment and backed by $25 million in Series A funding, launched Feb. 5.
Paige.AI uses artificial intelligence to help pathologists compile and interpret relevant patient data to guide diagnosis and treatment decisions. The startup's clinical decision support solutions will initially center on applications for breast and prostate cancers.
The company also signed a comprehensive license agreement with New York City-based Memorial Sloan Kettering Cancer Center to gain access to the hospital's library of 25 million pathology slides and intellectual property in the computational pathology field.
Under the agreement, Paige.AI will help Memorial Sloan Kettering digitize millions of archived pathology slides and leverage this data to train its clinical decision support algorithms.
"With computational pathology, pathologists can redirect their efforts toward more sophisticated tasks, such as integrating histologic findings with other diagnostic analyses," said David Klimstra, MD, pathology director of Paige.AI and chairman of the pathology department at Memorial Sloan Kettering.